Sg3 Management, LLC Kiniksa Pharmaceuticals, Ltd. Call Options Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$7.6 - $11.41 $304,000 - $456,400	-40,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$9.3 - $12.37 $139,500 - $185,550	-15,000 Reduced 27.27%	40,000 $398,000
Q4 2021 Feb 15, 2022	BUY	$10.39 - $15.15 $571,450 - $833,250	55,000 New	55,000 $647,000
Q3 2021 Nov 15, 2021	SELL	$11.39 - $16.23 $170,850 - $243,450	-15,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$13.22 - $19.09 $750,896 - $1.08 Million	-56,800 Reduced 79.11%	15,000 $209,000
Q1 2021 May 17, 2021	BUY	$16.68 - $23.97 $697,224 - $1 Million	41,800 Added 139.33%	71,800 $1.33 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $21.15 $222,000 - $317,250	15,000 Added 100.0%	30,000 $530,000
Q3 2020 Nov 13, 2020	BUY	$15.21 - $25.53 $228,150 - $382,950	15,000 New	15,000 $230,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $693M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.